-
Dong-A ST launches 'Imuldosa' in major European countries one after another…Gearing up for full-scale U.S. market entry next month
-
Daewoong Pharmaceutical launches ‘Fexuclue’ for gastroesophageal reflux disease treatment in India… Aiming at KRW 1.4 trillion market
-
ENCell accelerates technology transfer of CMT treatment candidate EN001…Japan set as first target market
-
AstraZeneca Korea's '스피드 바카라 사이트': Korea’s only approved treatment for limited-stage small cell lung cancer < ENGLISH NEWS
-
강원 랜드 바카라amp;VX: "강원 랜드 바카라 transfer deal with major pharmaceutical firm imminent…Aiming for KRW 3 trillion market cap."
-
"Lazertinib + amivantamab shows an expected mOS of 55 months, may be designated as 'preferred therapy' this year"
-
인터넷 바카라 사이트 “레이저티닙+아미반타맙, mOS 55개월도 기대…연내 ‘선호요법’ 등재 유력” < The
-
Celltrion to buy back additional KRW 100 billion in shares to boost under안전한 바카라 사이트d corporate 안전한 바카라 사이트 < ENGLISH
-
Coreline Soft launches AI-powered integrated thoracic diagnosis solution in Thailand
-
L&K Biomed sees rising global uptake of 'AccelFix-XT' with successful surgeries in UK and Vietnam
-
[AACR] Huonslab Reports Enhanced Bioavailability of SC Infliximab with HyDIFFUZE™ in Rats; AACR 2025 Abstract Selected
-
MEDI.SOLA secures KRW 13 billion Series A funding to officially launch personalized food care solution business